HOME 2018-03-18T02:57:55+00:00

Hypoxia Responses in Physiology and Pathogenesis

Changes in tissue oxygen levels occur under pathological conditions and physiologically during development. The laboratory of Volker Haase studies hypoxia response pathways and their therapeutic applications in tissue injury, erythropoiesis and iron metabolism, inflammation, kidney development and tumorigenesis.

Read More

Volker Haase Lab

advancing HIF biology and HIF-based therapies

Haase Lab in 2017

Mitochondria in renal epithelium

Erythropoietin-producing cells in the kidney
(red fluorescent signal)

Mechanisms of Renal Hypoxia

HIF activation in hepatocytes results in fatty livers

The laboratory of Professor Volker H. Haase studies hypoxia response pathways and their therapeutic applications in erythropoiesis and iron metabolismtissue injury and ischemic pre-conditioning, inflammation, kidney development and tumorigenesis. The Haase lab has largely focused on the hypoxia-inducible factor (HIF) pathway, its regulation by prolyl hydroxylase domain (PHD) oxygen sensors and the von Hippel-Lindau (VHL) tumor suppressor. Haase group members take advantage of cutting-edge mouse genetics, biochemical, metabolomic and single cell approaches to study the PHD/HIF pathway in the setting of acute and chronic kidney disease as well as other conditions.

For career opportunities in the Haase lab click here, for recent publications from our group please click here.

Haase Lab News

Research news

(click for larger)

in KI

Haase lab identifies a new role for HIF-PHD oxygen sensors in kidney development

December 2017

Insufficient oxygenation during pregnancy negatively influences kidney development, which predisposes to chronic kidney disease at later stages in life. Kobayashi et al. demonstrate that deletion of HIF prolyl-hydroxylase (PHD) 2 and 3, in FoxD1 lineage cells reduces kidney size and inhibits nephrogenesis in mice. Temporospatial expression pattern and studies on additional knockouts suggest the involvement of hypoxia-inducible factor (HIF)-2.

click to view pdf paper
link to research themes in the Haase lab

Paper accepted on the clinical effects of HIF-PHI vadadustat in hemodialysis patients

February 2018

” Effects of Vadadustat on Hemoglobin Concentrations in Patients Receiving Hemodialysis Previously Treated with Erythropoiesis Stimulating Agents “

Congratulations to the authors:  Volker H. Haase, Glenn M. Chertow, Geoffrey A. Block, Pablo E. Pergola, Emil deGoma, Zeeshan Khawaja, Amit Sharma, Bradley J. Maroni and Peter A. McCullough.

Erythropoiesis-stimulating agents (ESAs) can correct anemia in chronic kidney disease (CKD) but are associated with increased risks of cardiovascular events. Vadadustat, an inhibitor of hypoxia-inducible factor prolyl-4-hydroxylase domain (HIF-PHD) dioxygenases, is an oral investigational agent in development for the treatment of anemia in patients with CKD. read more…

click here for a link to erythropoiesis, iron metabolism and renal anemia

click here for teaching on renal anemia 

International meetings

Haase Lab will present at the upcoming Keystone Meeting on “Therapeutic Targeting of Hypoxia-Sensitive Pathways” at Oxford University

April 10-15, 2018

You can meet Professor Haase and other group members at this conference in April.

meeting info

meeting program

Volker Haase to speak at the 63rd meeting of the Japanese Society for Dialysis Therapy (JSDT) in Kobe, Japan

June 29-July 1, 2018

At this meeting Professor Haase will discuss HIF-PHD inhibition for the treatment of renal anemia.

meeting info